Download Files:
Products Details
Product Description
– Tulmimetostat (CPI-0209) is an orally active EZH1/EZH2 inhibitor. Tulmimetostat has antitumor activity and is used in a variety of solid tumor studies[1][2][3][4].
Web ID
– HY-145602
Shipping
– Room temperature
Applications
– Cancer-programmed cell death
Molecular Formula
– C28H36ClN3O5S
References
– [1]WHO Drug Information, Vol. 35, No. 4, 2021. Geneva: World Health Organization; 2022.|[2]Drescher C, et al. EZH2/EZH1 inhibitor tulmimetostat (CPI-0209): preliminary phase II results and first biomarker findings in patients with arid1a-mutant ovarian clear cell or endometrial carcinomas (OCCC/EC) 2023.|[3]Morschhauser F, et al. Taking the EZ way: Targeting enhancer of zeste homolog 2 in B-cell lymphomas. Blood Rev. 2022 Nov;56:100988.|[4]Qiu J, et al. The complex role of EZH2 in the tumor microenvironment: opportunities and challenges for immunotherapy combinations. Future Med Chem. 2020 Aug;12(15):1415-1430.
CAS Number
– 2567686-02-4
Molecular Weight
– 562.12
SMILES
– CC1=C2C(O[C@@](O2)([C@]3([H])CC[C@](N4CC(C4)OC)([H])CC3)C)=C(C=C1C(NCC5=C(C=C(NC5=O)C)SC)=O)Cl
Clinical Information
– Phase 2
Research Area
– Cancer
Solubility
– 10 mM in DMSO
Target
– Histone Methyltransferase
Isoform
– EZH1;EZH2
Pathway
– Epigenetics
Product type
– Reference compound
Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.
